Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Stock (NASDAQ: EXEL) stock price, news, charts, stock research, profile.
Day Range16.990 - 17.930 | 52 Wk Range14.870 - 23.400 | Open / Close17.000 / 17.760 | Float / Outstanding285.391M / 324.087M |
Vol / Avg.3.425M / 2.323M | Mkt Cap5.756B | P/E31.714 | 50d Avg. Price16.650 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float285.391M | EPS0.960 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-09 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.030 | 0.0900 | ||||
REV | 417.500M | 423.917M | 6.417M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Exelixis (NASDAQ: EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Exelixis (NASDAQ: EXEL) was reported by Piper Sandler on Wednesday, February 8, 2023. The analyst firm set a price target for 32.00 expecting EXEL to rise to within 12 months (a possible 80.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Exelixis (NASDAQ: EXEL) is $17.76 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Exelixis.
Exelixis’s Q1 earnings are confirmed for Tuesday, May 9, 2023.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.